CXCR3 and neoplasm: This may also explain why peripheral (systemic) administration of CXCL9-Fc or CXCL10-Fc limits tumor growth even though systemic administration of these agents would be expected to compromise the chemokine gradients that allow the endogenous CXCR3 ligands to attract T cells into the tumors.